Literature DB >> 26438310

The effects of visceral obesity and androgens on bone: trenbolone protects against loss of femoral bone mineral density and structural strength in viscerally obese and testosterone-deficient male rats.

D G Donner1, G E Elliott2, B R Beck3, M R Forwood4, E F Du Toit2.   

Abstract

SUMMARY: In males, visceral obesity and androgen deficiency often present together and result in harmful effects on bone. Our findings show that both factors are independently associated with adverse effects on femoral bone structure and strength, and trenbolone protects rats from diet-induced visceral obesity and consequently normalises femoral bone structural strength.
INTRODUCTION: In light of the rapidly increasing incidence of obesity and osteoporosis globally, and recent conjecture regarding the effects of visceral adiposity and testosterone deficiency on bone health, we investigated the effects of increased visceral adipose tissue (VAT) mass on femoral bone mineral density (BMD), structure and strength in normal weight rats with testosterone deficiency.
METHODS: Male Wistar rats (n = 50) were fed either standard rat chow (CTRL, n = 10) or a high-fat/high-sugar diet (HF/HS, n = 40). Following 8 weeks of feeding, rats underwent sham surgery (CTRL, n = 10; HF/HS, n = 10) or orchiectomy (HF/HS + ORX, n = 30). Following a 4-week recovery period, mini-osmotic pumps containing either vehicle (CTRL, n = 10; HF/HS, n = 10; HF/HS + ORX, n = 10), 2.0 mg kg day(-1), testosterone (HF/HS + ORX + TEST, n = 10) or 2.0 mg kg day(-1) trenbolone (HF/HS + ORX + TREN, n = 10) were implanted for 8 weeks of treatment. Dual-energy X-ray absorptiometry and three-point bending tests were used to assess bone mass, structure and strength of femora.
RESULTS: Diet-induced visceral obesity resulted in decreased bone mineral area (BMA) and content (BMC) and impaired femoral stiffness and strength. Orchiectomy further impaired BMA, BMC and BMD and reduced energy to failure in viscerally obese animals. Both TEST and TREN treatment restored BMA, BMC, BMD and energy to failure. Only TREN reduced visceral adiposity and improved femoral stiffness and strength.
CONCLUSIONS: Findings support a role for both visceral adiposity and testosterone deficiency as independent risk factors for femoral osteoporosis, adverse bone geometry and impaired bone strength in male rats. Trenbolone may be a more effective candidate for androgen replacement therapy than testosterone in viscerally obese testosterone-deficient males.

Entities:  

Keywords:  Bone mineral density; Osteoporosis; Testosterone deficiency; Trenbolone; Visceral adipose tissue; Visceral obesity

Mesh:

Substances:

Year:  2015        PMID: 26438310     DOI: 10.1007/s00198-015-3345-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  47 in total

1.  Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

Authors:  S Khosla; L J Melton; E J Atkinson; W M O'Fallon
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

2.  Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity.

Authors:  Yen Kim Luu; Encarnacion Capilla; Clifford J Rosen; Vicente Gilsanz; Jeffrey E Pessin; Stefan Judex; Clinton T Rubin
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

Review 3.  Recent developments in antiandrogens and selective androgen receptor modulators.

Authors:  Bernard Haendler; Arwed Cleve
Journal:  Mol Cell Endocrinol       Date:  2011-06-16       Impact factor: 4.102

4.  A comparison of mechanical properties derived from multiple skeletal sites in mice.

Authors:  Jennifer L Schriefer; Alexander G Robling; Stuart J Warden; Adam J Fournier; James J Mason; Charles H Turner
Journal:  J Biomech       Date:  2005-03       Impact factor: 2.712

5.  17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.

Authors:  Joshua F Yarrow; Christine F Conover; Sean C McCoy; Judyta A Lipinska; Cesar A Santillana; John M Hance; Darryl F Cannady; Tisha D VanPelt; Joshua Sanchez; Bryan P Conrad; Jennifer E Pingel; Thomas J Wronski; Stephen E Borst
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-25       Impact factor: 4.310

6.  Improvements in body composition, cardiometabolic risk factors and insulin sensitivity with trenbolone in normogonadic rats.

Authors:  Daniel G Donner; Belinda R Beck; Andrew C Bulmer; Alfred K Lam; Eugene F Du Toit
Journal:  Steroids       Date:  2014-12-30       Impact factor: 2.668

7.  Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men.

Authors:  Howard A Fink; Susan K Ewing; Kristine E Ensrud; Elizabeth Barrett-Connor; Brent C Taylor; Jane A Cauley; Eric S Orwoll
Journal:  J Clin Endocrinol Metab       Date:  2006-07-18       Impact factor: 5.958

8.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

9.  Differences in the biotransformation of a 17 beta-hydroxylated steroid, trenbolone acetate, in rat and cow.

Authors:  J Pottier; C Cousty; R J Heitzman; I P Reynolds
Journal:  Xenobiotica       Date:  1981-07       Impact factor: 1.908

10.  Gender differences in diagnostic values of visceral fat area and waist circumference for predicting metabolic syndrome in Koreans.

Authors:  Hong Il Kim; Jin Taek Kim; Sung Hoon Yu; Soo Heon Kwak; Hak Chul Jang; Kyong Soo Park; Seong Yeon Kim; Hong Kyu Lee; Young Min Cho
Journal:  J Korean Med Sci       Date:  2011-06-20       Impact factor: 2.153

View more
  3 in total

Review 1.  Obesity is a concern for bone health with aging.

Authors:  Sue A Shapses; L Claudia Pop; Yang Wang
Journal:  Nutr Res       Date:  2017-01-18       Impact factor: 3.315

2.  FGF-2 Gene Polymorphism in Osteoporosis among Guangxi's Zhuang Chinese.

Authors:  Xiaoyun Bin; Chaowen Lin; Xiufeng Huang; Qinghui Zhou; Liping Wang; Cory J Xian
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

3.  Stanozolol promotes osteogenic gene expression and apposition of bone mineral in vitro.

Authors:  Giulia Ghiacci; Simone Lumetti; Edoardo Manfredi; Daniele Mori; Guido Maria Macaluso; Roberto Sala
Journal:  J Appl Oral Sci       Date:  2018-11-08       Impact factor: 2.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.